All In Biotech

Drug Trial Radar · NCT07487766

The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis

A Phase 1/2, Single-Blinded Trial to Evaluate the Safety and Efficacy of Intra-Articular (IA) Injection of XytriX in Adult Subjects With Grade I-IV Knee Osteoarthritis (KOA)

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

May 2026

Primary completion

May 2027

Study completion Dec 2028

Sponsor

Lead sponsor
TricelX Inc.Industry
Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to study the safety and efficacy of XytriX, an umbilical cord-derived stem cell product, in the treatment of Grade I-IV knee osteoarthritis.

Conditions

  • Osteoarthritis

Interventions

  • Mesenchymal Stem Cell InjectionBiological

    Subjects will receive an intra-articular injection of mesenchymal stem cells derived from umbilical cord tissue

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Knee Injury and Osteoarthritis Outcome ScoreTime frame: 24 months
  2. Western Ontario and McMaster Universities Osteoarthritis IndexTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TriCelX

    Frisco, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.